Depression Treatment and Risk for Cardiovascular Disease
NCT ID: NCT06170255
Last Updated: 2023-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
16 participants
INTERVENTIONAL
2014-03-06
2017-10-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psychotherapy and Cardiovascular Risk Factors in Depression
NCT02787148
Beating the Blues for Your Heart
NCT01605552
Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)
NCT01692574
Biological CVD Risk Factors in Older Depressed Patients
NCT00318864
Interpersonal Psychotherapy for Depression in People With Heart Failure
NCT00353223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depression treatment
Participants receive behavioral therapy for depression
Behavioral Activation (BA)
Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Behavioral Activation (BA)
Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Meet diagnostic criteria for major depressive disorder
Framingham risk score indicating a greater than negligible 10-year risk (3% or greater) for cardiovascular disease.
Levels of depressive symptoms of at least moderate level (beck depression inventory II score \> 19 of 63 possible points; or a Hamilton depression rating scale \> 12 of 50 possible points)
Exclusion Criteria
Score of \>1 on any single item of the Beck Scale for Suicidal Ideation
Score of \> 1 on the item assessing suicidal ideation on the beck depression inventory II.
Psychiatric diagnoses that could potentially interfere with depression treatment (current post traumatic stress disorder, bipolar I disorder, obsessive-compulsive disorder, bulimia or anorexia nervosa, schizophrenia, and panic disorder)
Current use of an antidepressant medication
Currently in psychotherapy.
Current use of a beta blocker, anxiolytic (benzodiazepine), antipsychotic agent
Diagnosis of CVD.
21 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Institute of Mental Health (NIMH)
NIH
East Carolina University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthew Whited
Associate Professor of Psychology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.